MCID: AST007
MIFTS: 49

Astrocytoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Astrocytoma

MalaCards integrated aliases for Astrocytoma:

Name: Astrocytoma 12 76 29 55 6 44 15 73
Cerebral Astrocytoma 12 73
Astrocytoma, No Icd-O Subtype 12
Astrocytoma of Cerebrum 12
Astrocytoma of Brain 12
Astrocytic Tumor 12
Astroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3069
MeSH 44 D001254
SNOMED-CT 68 38713004

Summaries for Astrocytoma

Disease Ontology : 12 A malignant glioma that is has material basis in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord.

MalaCards based summary : Astrocytoma, also known as cerebral astrocytoma, is related to pilomyxoid astrocytoma and glioblastoma. An important gene associated with Astrocytoma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic). The drugs Afinitor and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and endothelial.

Wikipedia : 76 Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells,... more...

Related Diseases for Astrocytoma

Diseases in the Astrocytoma family:

Juvenile Astrocytoma

Diseases related to Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 pilomyxoid astrocytoma 33.5 FGFR1 H19
2 glioblastoma 31.6 FGFR1 H19 HOTAIR HOXA-AS3 IDH1 MIR21
3 glioma 31.3 CASC2 FGFR1 H19 HOTAIR IDH1 MIR21
4 neuroblastoma 31.0 FGFR1 H19 HOTAIR MIR106A PTPN11 SNHG1
5 medulloblastoma 30.8 FGFR1 H19 HOTAIR IDH1
6 malignant glioma 30.5 CASC2 CCDC26 HOTAIR HOXA-AS3
7 leukemia, acute myeloid 30.4 CCDC26 HOTAIR IDH1 MIR21 PTPN11
8 renal cell carcinoma, nonpapillary 30.2 CASC2 H19 HOTAIR LBX2-AS1
9 breast cancer 30.2 CASC2 CCDC26 FGFR1 H19 HOTAIR IDH1
10 myeloma, multiple 30.1 H19 HOTAIR IDH1 PTPN11 TP73-AS1
11 osteogenic sarcoma 30.1 CASC2 H19 HOTAIR SNHG1
12 prostate cancer 30.0 CASC2 FGFR1 H19 HOTAIR MIR106A MIR21
13 pilocytic astrocytoma 12.6
14 fibrillary astrocytoma 12.6
15 grade iii astrocytoma 12.5
16 subependymal giant cell astrocytoma 12.5
17 melanoma-astrocytoma syndrome 12.4
18 spinal cord astrocytoma 12.2
19 cerebellar astrocytoma 12.2
20 gemistocytic astrocytoma 12.2
21 protoplasmic astrocytoma 12.2
22 juvenile pilocytic astrocytoma 12.2
23 childhood pilocytic astrocytoma 12.1
24 juvenile astrocytoma 12.1
25 pilocytic astrocytoma of cerebellum 12.1
26 optic nerve astrocytoma 12.1
27 diencephalic astrocytomas 12.1
28 desmoplastic infantile astrocytoma 12.1
29 childhood cerebral astrocytoma 12.0
30 desmoplastic infantile astrocytoma/ganglioglioma 12.0
31 glioma susceptibility 1 12.0
32 childhood optic tract astrocytoma 12.0
33 mixed astrocytoma-ependymoma 12.0
34 mixed oligodendroglioma-astrocytoma 12.0
35 pineal gland astrocytoma 11.9
36 adult brainstem astrocytoma 11.9
37 childhood brainstem astrocytoma 11.9
38 mixed astrocytoma-ependymoma-oligodendroglioma 11.9
39 cauda equina intradural extramedullary astrocytoma 11.9
40 cerebellar astrocytoma, childhood 11.9
41 oligoastrocytoma 11.9
42 tuberous sclerosis 11.5
43 glioblastoma multiforme 11.4
44 brain stem astrocytic neoplasm 11.4
45 diencephalic syndrome 11.4
46 subependymoma 11.3
47 li-fraumeni syndrome 11.3
48 li-fraumeni syndrome 2 11.3
49 pleomorphic xanthoastrocytoma 11.3
50 adult infiltrating astrocytic neoplasm 11.1

Graphical network of the top 20 diseases related to Astrocytoma:



Diseases related to Astrocytoma

Symptoms & Phenotypes for Astrocytoma

Drugs & Therapeutics for Astrocytoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999

Drugs for Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 607)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
5
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
6 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
7
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
8 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
12 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
13 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
14 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1
16
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
17
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 52-24-4 5453
18
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
19
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 6055-19-2, 50-18-0 2907
20
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
21
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
22
Tranexamic Acid Approved Phase 3 1197-18-8 5526
23
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
24
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
25
Methotrexate Approved Phase 3,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
26
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
27
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
28
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
29
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
30
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
31
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
32
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
33
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
34
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
35
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
36
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 100286-90-6, 97682-44-5 60838
37
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 216974-75-3
38
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 557795-19-4, 341031-54-7 5329102
39
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
40
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable 106-60-5 137
41
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
42
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
43
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
44
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
45
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
46
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 149647-78-9 5311
47
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
48
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
50
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 1499)
# Name Status NCT ID Phase Drugs
1 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Unknown status NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
2 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
3 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
4 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
5 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
6 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
8 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
9 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
10 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
11 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
12 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
13 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
14 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
15 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
16 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
17 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3 Everolimus;Placebo
18 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
19 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
20 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
21 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
22 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
23 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
24 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
25 Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
26 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
27 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
28 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
29 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
30 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
31 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
32 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
33 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
34 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
35 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
36 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
37 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
38 XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Completed NCT00088166 Phase 3 hCRF;placebo hCRF
39 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
40 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
41 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
42 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
43 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
44 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
45 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
46 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
47 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
48 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
49 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
50 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib

Search NIH Clinical Center for Astrocytoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: astrocytoma

Genetic Tests for Astrocytoma

Genetic tests related to Astrocytoma:

# Genetic test Affiliating Genes
1 Astrocytoma 29

Anatomical Context for Astrocytoma

MalaCards organs/tissues related to Astrocytoma:

41
Brain, Spinal Cord, Endothelial, Cerebellum, T Cells, Bone, Pituitary

Publications for Astrocytoma

Articles related to Astrocytoma:

(show top 50) (show all 2193)
# Title Authors Year
1
Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma. ( 30251337 )
2019
2
Long-term health and social function in adult survivors of paediatric astrocytoma: A report from the Childhood Cancer Survivor Study. ( 30528801 )
2019
3
Long-term outcomes of primarily metastatic juvenile pilocytic astrocytoma in children. ( 29125440 )
2018
4
iASPP, a microRNAa89124 target, is aberrantly expressed in astrocytoma and regulatesA malignantA gliomaA cellA migration and viability. ( 29257240 )
2018
5
Trapped ventricle after laser ablation of a subependymal giant cell astrocytoma complicated by intraventricular gadolinium extravasation: case report. ( 29451453 )
2018
6
Intermediate Pilomyxoid Astrocytoma in the Cerebellum of a 5-Year-Old Boy. ( 29717569 )
2018
7
Supratentorial extension of large cerebellar pilocytic astrocytoma in adult. ( 29446978 )
2018
8
MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating I^-catenin and causing activation of FOXO3a. ( 29399110 )
2018
9
Reader response: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807920 )
2018
10
Durable response to bevacizumab in adults with recurrent pilocytic astrocytoma. ( 29629823 )
2018
11
Cystathionine Promotes the Proliferation of Human Astrocytoma U373 Cells. ( 29848703 )
2018
12
Management and survival of adult patients with pilocytic astrocytoma in the National Cancer Database. ( 29427814 )
2018
13
Long-Term Remission of Recurrent Brainstem Pilocytic Astrocytoma with Neuraxis Dissemination Using Recombinant Human Endostatin After Failure of Vincristine and Carboplatin. ( 29203315 )
2018
14
Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma. ( 29805628 )
2018
15
Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. ( 29180079 )
2018
16
Co-occurrence of astrocytoma and astroblastoma: Case report and literature review. ( 29939429 )
2018
17
Giant congenital melanocytic nevus associated with cerebellar astrocytoma. ( 29619995 )
2018
18
Pilocytic astrocytoma with leptomeningeal spread in a patient with incontinentia pigmenti presenting with unilateral nystagmus. ( 29171168 )
2018
19
An elderly case of malignant small cell glioma with hemorrhage coexistent with a calcified pilocytic astrocytoma component in the cerebellar hemisphere. ( 29851180 )
2018
20
CDKN2A/B Loss Is Associated with Anaplastic Transformation in a Case of NTRK2 Fusion-positive Pilocytic Astrocytoma. ( 29804288 )
2018
21
Diagnostic accuracy of diffusion weighted imaging for differentiation of supratentorial pilocytic astrocytoma and pleomorphic xanthoastrocytoma. ( 29797290 )
2018
22
A low-grade astrocytoma in a sixteen-year-old boy with a 7q11.22 deletion. ( 29445462 )
2018
23
Pilocytic astrocytoma with spontaneous malignant transformation with intracranial and skeletal dissemination: case report and review of the literature. ( 29745267 )
2018
24
Combined Diffuse Astrocytoma and Pleomorphic Xanthoastrocytoma grade III sharing IDH1 R132H mutation. ( 29859360 )
2018
25
MR Imaging Features of Anaplastic Pleomorphic Xanthoastrocytoma Mimicking High-Grade Astrocytoma. ( 29903923 )
2018
26
Dysembryoplastic neuroepithelial tumor-like pilocytic astrocytoma: A case report. ( 29768357 )
2018
27
Rare compound heterozygous variants in PNKP identified by whole exome sequencing in a German patient with ataxia-oculomotor apraxia 4 and pilocytic astrocytoma. ( 29498415 )
2018
28
Efficacy and safety of everolimus in patients younger than 12a8^months with congenital subependymal giant cell astrocytoma. ( 29395661 )
2018
29
Novel suprasellar location of desmoplastic infantile astrocytoma and ganglioglioma: a single institution's experience. ( 29979130 )
2018
30
Pediatric cerebellar pilocytic astrocytoma presenting with spontaneous intratumoral hemorrhage. ( 29569086 )
2018
31
Atypical subependymal giant cell astrocytoma and neonatal tuberous sclerosis. ( 29555882 )
2018
32
Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomised EXIST-1 and EXIST-2 studies. ( 29569806 )
2018
33
High-level Sp1 is Associated with Proliferation, Invasion, and Poor Prognosis in Astrocytoma. ( 29948615 )
2018
34
The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. ( 28993887 )
2018
35
Simultaneous supratentorial and infratentorial pilocytic astrocytoma in an adult patient with concurrent neurofibromatosis type 1 and HIV infection. ( 29908379 )
2018
36
Desmoplastic non- infantile astrocytoma/Ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation. ( 29902580 )
2018
37
Expression of CD133 as a Putative Prognostic Biomarker to Predict Intracranial Dissemination of Primary Spinal Cord Astrocytoma. ( 29180077 )
2018
38
Mitogen-activated protein kinase in gliosis and pilocytic astrocytoma. ( 29168690 )
2018
39
Hypoxia Detection in Infiltrative Astrocytoma: Ferumoxytol-based Quantitative BOLD MRI with Intraoperative and Histologic Validation. ( 29944077 )
2018
40
<i>FGFR1</i> tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia. ( 29610389 )
2018
41
Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. ( 29330645 )
2018
42
Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. ( 29973652 )
2018
43
Effect of brefelamide on proliferation of 1321N1 human astrocytoma cells induced by glial cell line-derived neurotrophic factor. ( 29441947 )
2018
44
Stachydrine suppresses viability &amp;amp; migration of astrocytoma cells via CXCR4/ERK &amp;amp; CXCR4/Akt pathway activity. ( 29873242 )
2018
45
Editors' note: Pilocytic astrocytoma with anaplasia arising from the optic chiasm in a very elderly patient. ( 29807919 )
2018
46
Pseudoprogression successfully treated with bevacizumab in a child with spinal pilocytic astrocytoma. ( 29804214 )
2018
47
Spinal cord astrocytoma: a unique presentation of abdominal pain. ( 29487669 )
2018
48
Lacunar Stroke, Cavernous Angioma, and Fusiform Aneurysm Due to Irradiation for Pilocytic Astrocytoma-A Case Report. ( 29673614 )
2018
49
Intraorbital ancient pilocytic astrocytoma of the optic nerve in neurofibromatosis type 1 patient presenting with sudden ocular pain. ( 29511546 )
2018
50
Orbital tumor associated with a microphthalmic eye and colobomatous cleft: Pilocytic astrocytoma (glioma) or massive retinal gliosis. ( 29755278 )
2018

Variations for Astrocytoma

ClinVar genetic disease variations for Astrocytoma:

6 (show all 38)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
2 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
3 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
4 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
5 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
6 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
7 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
8 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869
9 TP53 NM_000546.5(TP53): c.848G> A (p.Arg283His) single nucleotide variant Conflicting interpretations of pathogenicity rs371409680 GRCh37 Chromosome 17, 7577090: 7577090
10 TP53 NM_000546.5(TP53): c.848G> A (p.Arg283His) single nucleotide variant Conflicting interpretations of pathogenicity rs371409680 GRCh38 Chromosome 17, 7673772: 7673772
11 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
12 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
13 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic rs779707422 GRCh37 Chromosome 8, 38274849: 38274849
14 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic rs779707422 GRCh38 Chromosome 8, 38417331: 38417331
15 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
16 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh38 Chromosome 8, 38414790: 38414790
17 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
18 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
19 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
20 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
21 FGFR1 NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn) single nucleotide variant Likely pathogenic rs1057519897 GRCh37 Chromosome 8, 38272306: 38272306
22 FGFR1 NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn) single nucleotide variant Likely pathogenic rs1057519897 GRCh38 Chromosome 8, 38414788: 38414788
23 FGFR1 NM_023110.2(FGFR1): c.1636A> G (p.Asn546Asp) single nucleotide variant Likely pathogenic rs1057519898 GRCh37 Chromosome 8, 38274851: 38274851
24 FGFR1 NM_023110.2(FGFR1): c.1636A> G (p.Asn546Asp) single nucleotide variant Likely pathogenic rs1057519898 GRCh38 Chromosome 8, 38417333: 38417333
25 FGFR1 NM_023110.2(FGFR1): c.1543A> G (p.Met515Val) single nucleotide variant Likely pathogenic rs1057519899 GRCh37 Chromosome 8, 38275397: 38275397
26 FGFR1 NM_023110.2(FGFR1): c.1543A> G (p.Met515Val) single nucleotide variant Likely pathogenic rs1057519899 GRCh38 Chromosome 8, 38417879: 38417879
27 H3F3A NM_002107.4(H3F3A): c.83A> T (p.Lys28Met) single nucleotide variant Likely pathogenic rs1057519903 GRCh37 Chromosome 1, 226252135: 226252135
28 H3F3A NM_002107.4(H3F3A): c.83A> T (p.Lys28Met) single nucleotide variant Likely pathogenic rs1057519903 GRCh38 Chromosome 1, 226064434: 226064434
29 ARID1A NM_006015.5(ARID1A): c.60_62dup (p.Pro21_Ser22insPro) duplication Conflicting interpretations of pathogenicity rs748085214 GRCh38 Chromosome 1, 26696463: 26696465
30 ARID1A NM_006015.5(ARID1A): c.60_62dup (p.Pro21_Ser22insPro) duplication Conflicting interpretations of pathogenicity rs748085214 GRCh37 Chromosome 1, 27022954: 27022956
31 ARID1B NM_020732.3(ARID1B): c.751T> G (p.Cys251Gly) single nucleotide variant Uncertain significance GRCh37 Chromosome 6, 157099814: 157099814
32 ARID1B NM_020732.3(ARID1B): c.751T> G (p.Cys251Gly) single nucleotide variant Uncertain significance GRCh38 Chromosome 6, 156778680: 156778680
33 EPHA5 NM_004439.7(EPHA5): c.1043A> G (p.Asp348Gly) single nucleotide variant Uncertain significance rs200932017 GRCh38 Chromosome 4, 65495411: 65495411
34 EPHA5 NM_004439.7(EPHA5): c.1043A> G (p.Asp348Gly) single nucleotide variant Uncertain significance rs200932017 GRCh37 Chromosome 4, 66361129: 66361129
35 KMT2D NM_003482.3(KMT2D): c.15876G> C (p.Glu5292Asp) single nucleotide variant Uncertain significance GRCh37 Chromosome 12, 49418638: 49418638
36 KMT2D NM_003482.3(KMT2D): c.15876G> C (p.Glu5292Asp) single nucleotide variant Uncertain significance GRCh38 Chromosome 12, 49024855: 49024855
37 TSC1 NM_000368.4(TSC1): c.359T> C (p.Leu120Pro) single nucleotide variant Uncertain significance GRCh38 Chromosome 9, 132925591: 132925591
38 TSC1 NM_000368.4(TSC1): c.359T> C (p.Leu120Pro) single nucleotide variant Uncertain significance GRCh37 Chromosome 9, 135800978: 135800978

Cosmic variations for Astrocytoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10672 TP53 central nervous system,cerebrum,glioma,astrocytoma Grade II c.577C>T p.H193Y 17:7674954-7674954 4
2 COSM10656 TP53 central nervous system,cerebrum,glioma,astrocytoma Grade II c.742C>T p.R248W 17:7674221-7674221 4
3 COSM476 BRAF central nervous system,cerebrum,glioma,astrocytoma Grade II c.1799T>A p.V600E 7:140753336-140753336 4

Copy number variations for Astrocytoma from CNVD:

7 (show top 50) (show all 436)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13337 1 1 124300000 Loss Astrocytoma
2 13347 1 1 125000000 Deletion Astrocytoma
3 13376 1 1 2300000 Amplification AURKAIP1 Astrocytoma
4 13377 1 1 2300000 Amplification C1orf159 Astrocytoma
5 13378 1 1 2300000 Amplification CDC2L1 Astrocytoma
6 13379 1 1 2300000 Amplification CDC2L2 Astrocytoma
7 13380 1 1 2300000 Amplification CPSF3L Astrocytoma
8 13381 1 1 2300000 Amplification GNB1 Astrocytoma
9 13382 1 1 2300000 Amplification HES4 Astrocytoma
10 13383 1 1 2300000 Amplification ISG15 Astrocytoma
11 13386 1 1 2300000 Amplification MIB2 Astrocytoma
12 13387 1 1 2300000 Amplification MMP23A Astrocytoma
13 13388 1 1 2300000 Amplification NOC2L Astrocytoma
14 13389 1 1 2300000 Amplification PRKCZ Astrocytoma
15 13390 1 1 2300000 Amplification SDF4 Astrocytoma
16 13391 1 1 2300000 Amplification SLC35E2 Astrocytoma
17 13757 1 1 28000000 Deletion Astrocytoma
18 13760 1 1 28000000 Deletion Astrocytoma
19 16428 1 124300000 247249719 Gain Astrocytoma
20 16544 1 12700000 16200000 Deletion Astrocytoma
21 30468 1 243700000 249250621 Deletion AKT3 Astrocytoma
22 30469 1 243700000 249250621 Deletion SDCCAG8 Astrocytoma
23 30470 1 243700000 249250621 Deletion ZNF238 Astrocytoma
24 31970 1 32400000 34600000 Deletion Astrocytoma
25 32218 1 34600000 44100000 Deletion Astrocytoma
26 35014 1 59000000 68900000 Deletion Astrocytoma
27 36950 1 8384389 8404226 Deletion SLC45A1 Astrocytoma
28 46536 10 82000000 135374737 Loss Astrocytoma
29 48496 11 1 52900000 Loss Astrocytoma
30 67045 12 35400000 132349534 Loss Astrocytoma
31 67785 12 44600000 69800000 Gain Astrocytoma
32 75152 13 16000000 114142980 Loss Astrocytoma
33 89238 15 17000000 100338915 Gain Astrocytoma
34 97277 16 1 38200000 Loss Astrocytoma
35 97302 16 1 6300000 Amplification ABCA3 Astrocytoma
36 97303 16 1 6300000 Amplification AXIN1 Astrocytoma
37 97304 16 1 6300000 Amplification C1QTNF8 Astrocytoma
38 97305 16 1 6300000 Amplification CACNA1H Astrocytoma
39 97306 16 1 6300000 Amplification CREBBP Astrocytoma
40 97307 16 1 6300000 Amplification DNAJA3 Astrocytoma
41 97308 16 1 6300000 Amplification HMOX2 Astrocytoma
42 97309 16 1 6300000 Amplification IGFALS Astrocytoma
43 97310 16 1 6300000 Amplification MAGMAS Astrocytoma
44 97311 16 1 6300000 Amplification MAPK8IP3 Astrocytoma
45 97312 16 1 6300000 Amplification MMP25 Astrocytoma
46 97313 16 1 6300000 Amplification MPG Astrocytoma
47 97314 16 1 6300000 Amplification MRPL28 Astrocytoma
48 97315 16 1 6300000 Amplification MSLN Astrocytoma
49 97316 16 1 6300000 Amplification NME4 Astrocytoma
50 97317 16 1 6300000 Amplification NTHL1 Astrocytoma

Expression for Astrocytoma

Search GEO for disease gene expression data for Astrocytoma.

Pathways for Astrocytoma

GO Terms for Astrocytoma

Biological processes related to Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of vascular endothelial cell proliferation GO:1905564 8.62 FGFR1 MIR21

Sources for Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....